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Previously we have shown that bone marrow (BM)
transplantation (BMT) can attenuate progression of and even
ameliorate mesangial sclerosis (MS) in Wt1-heterozygous
mice. However, it is unclear whether BMT performed before
the onset of disease will prevent the development of MS.
To investigate whether intravenous (i.v.) or intrarenal (i.r.)
administration of BM have equal effects on the progression
of MS in Wt1-heterozygous mice, young Wt1-heterozygous
mice that had not yet developed renal disease were used as
recipients for BMT. After preconditioning with 750 cGy
radiation, mice were transplanted with one million wild-type
BM via i.v. or i.r. administration. All recipients and untreated
controls were assessed for urinary albumin loss, renal
pathology, and BM donor-derived renal cells over time.
Representative kidney samples were subjected to
transmission electron microscopy (TEM) analysis.
Interestingly, i.r. and i.v. administration of BM cells gave
comparable hematopoietic engraftment levels, and both
were able to prevent the onset of MS as assessed by
improved lifespan, renal function, renal histology, and TEM
analysis. Taken together, we show for the first time that MS
can be prevented if BMT is performed before disease onset.
Similar therapeutic effects were obtained whether the BM
was administered i.v. or i.r.
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Diffuse mesangial sclerosis (MS) is one of the most common
causes of infantile nephrotic syndrome, and is associated with
glomerular injury and rapid progression to end-stage renal
failure.1 In mice, decreased levels of Wt1 cause MS, as we and
others have observed in Wt1þ / mice.2,3
Several studies have indicated that bone marrow (BM)
contains renoprotective/renotropic cells,4–8 and we have
shown previously that transplantation of wild-type donor
BM cells into Wt1þ / mice (K-mice, hereafter) attenuates
the progression of MS.9 In this study, we tested whether the
route and timing of bone marrow transplantation (BMT) are
critical for optimizing the effects of transplanted BM cells.
RESULTS
F1 (FVB/NC57Bl/6) K-mice serve as a genetic model for
late-onset MS
K-mice on a pure FVB/N background develop albuminuria as
early as 3 weeks after birth, making them suboptimal for
assessing whether BMT can be used to prevent the
development of MS in adult mice. To overcome this
limitation, we mated FVB/N K-mice with C57Bl/6 wild-type
mice to obtain F1 FVB/NC57Bl/6 K-mice, which have a
significantly later onset time and slower progression of MS,
comparable to the originally described Wt1þ / mice on a
mixed background.2,3 In F1 FVB/NC57Bl/6 K-mice (n¼ 9)
at 2 months after birth, 66.7% were free of albuminuria (the
rest with very low level of albuminuria) and all had normal
histology. By 6 months, all developed MS with heavy
albuminuria (Figure 1).
Intrarenal infusion of BM allows for hematopoietic
engraftment
K-mice and their littermates (7–9 weeks old) were divided
into four groups: wild-type no-BMT control, K-mice no-
BMT control, wild-type BMT recipients, and K-mice BMT
recipients (Table 1). One million total wild-type BM cells
were transplanted either by tail vein or intrarenal (i.r.)
injection into the left kidney. Engraftment was examined by
green fluorescent protein (GFP) fluorescence of total
nucleated blood cells when mice were killed 6 months post-
transplantation. There was no statistical significance between
individual groups in terms of BM engraftment levels
(P40.05, Table 1). Next, the level of engraftment of GFPþ
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podocytes was examined by immunostaining with anti-Wt1
and anti-GFP antibodies on paraffin sections. Again, there
was no significant difference in the level of total donor-
derived podocytes between different groups (P40.05,
Table 1) or donor-derived renal interstitial cells (P40.05,
data not shown), indicating that the route of injection did
not affect the engraftment of donor cells.
Early BMT can prevent the development of MS
Urinary albumin loss was closely monitored throughout the
course of the experiments. Although untransplanted K-mice
show a progressive increase in albuminuria, 5 of 10 K-mice
(two intravenous, and three i.r.) had no albumin in their
urine for up to 6 months post-BMT, and three other
recipients had only low levels of albuminuria. For each
experimental group at different time points, the average
urinary albumin concentration standardized to creatinine
levels is shown in Figure 1. Of these eight K-mice that had
little to no albuminuria, seven had normal histology (Figure
2a). The three other transplanted K-mice with higher levels of
albuminuria had slight pathology with a small increase in
extracellular matrix in the glomerular tuft, but otherwise
normal tubular structure and interstitium. These 10 K-mice
recipients had an average histology score of 0.225. In
contrast, the untransplanted K-mice all developed severe
MS (mean histology score of 3.5) within the same 6-month
period. The results of an intensive podocyte number count
on Wt1-immunostained slides confirmed that BMT can
prevent the loss of podocytes (Figure 2b). Immunofluor-
escent study of the diaphragm slit using anti-nephrin
antibody also revealed the beneficial effect of BMT on
podocyte morphology in K-mice (data not shown), as the
staining pattern of nephrin is a sensitive indicator of
podocyte status. Moreover, TEM analysis indicated that
BMT using wild-type donors helped to maintain normal
podocyte foot processes in the Wt1þ / recipients. There
was no evidence of adverse effects of BMT on glomerular
mesangial cells, glomerular basement membrane, or endo-
thelial cells (Figure 2c). More important, the two kidneys of
individual i.r. recipients showed identical histology even
though only one kidney had BMT administered, suggesting
that the beneficial effect was derived from circulating BM
cells. The left and right kidneys had identical levels of donor-
derived cells as well (Figure 3).
DISCUSSION
The finding that 70% of K-mice recipients (n¼ 10) had
completely normal histology when BMT was performed before
disease onset suggests that it is possible to prevent, at least for
6 months, the development of MS in mice heterozygous for
the Wt1 locus. Moreover, we found that there is no advantage
to delivering BM cells directly into the kidney.
These data provide further evidence that BMT can attenu-
ate and even prevent the development of MS owing to Wt1
insufficiency, regardless of the route of transplantation. The
finding that wild-type and K recipients have comparable low
levels of donor-derived podocyte engraftment as observed
here and in our previous studies9 indicates that pre-existing
severe renal injury does not enhance donor-derived cells to
become podocytes and the therapeutic/preventive effect may
take place independent of donor-derived renal epithelial cells.
0
2
4
6
8
10
12
14
16
W
T K
W
T 
to
 K
i.v
.
W
T 
to
 K
i.r
.
W
T 
to
W
T 
i.v
.
W
T 
to
W
T 
i.r
.
Groups
*
0 month
2 months
4 months
6 months
Figure 1 | Quantification of urinary albumin by enzyme-linked
immunosorbent assay. X axis: six experimental groups, y axis:
albumin level standardized to creatinine. WT: wild-type untreated
group showing baseline levels of albuminuria. K: untreated K-mice
showing significant urinary albumin loss. WT to K i.v.: K-mice
recipients with wild-type BM via i.v. WT to K i.r., K-mice recipients with
wild-type BM via i.r. WT to WT i.v.: wild-type recipients with wild-type
BM via i.v. WT to WT i.r.: wild-type recipients with wild-type BM via i.r.
Samples collected 0, 2, 4, and 6 months post-BMT were assayed.
*No s.e.m. available because the number of mice for this time point
dropped to two.
Table 1 | Summary of BMT results
Groups N Route of BM injection Engraftment in BM
Survival
(6 months post-BMT) (%)
Donor-derived
podocytesa (%)
WT 3 N/A N/A 100 N/A
K 3 N/A N/A 67.8 N/A
BMT/WT 6 i.r. (n=2) 6577.1% 100 0.1570.07
i.v. (n=4) 80.376.5% 100 0.8670.56
BMT/K 10 i.r. (n=5) 81.378.5% 100 0.5070.16
i.v. (n=5) 86.374.2% 100 0.8170.86
BM, bone marrow; BMT, bone marrow transplant; BMT/WT, wild-type recipients; BMT/K, K-mice as recipients; N/A, not applicable; i.r., intrarenal.
All BM was from wild-type donors.
aPercentage of podocytes (Wt1+ nuclei within the glomeruli) that were GFP+.
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Further studies will help determine the underlying mechan-
ism of this beneficial effect, especially whether donor-derived
renal interstitial cells account for the therapeutic effects of
BMT.
MATERIALS AND METHODS
Mouse care and BMT
Wt1þ / mice (K-mice) were genotyped as described.2 In this
study, we used F1 K-mice (FVB/NC57Bl/6) owing to the late
onset of MS on this mixed genetic background.2,3 GFP mice
(C57BL/6-Tg(ACTbEGFP)1Osb/J) were from Jackson laboratory
(Bar Harbor, Maine)10 F1 GFP mice (C57BL/6-Tg(ACTbEGF-
P)1Osb/J FVB/N) were used as donors to match the genetic
background of the recipients. All mouse protocols were approved by
the Yale University Institutional Animal Care and Use Committee.
Donor BM isolation, and BMT were carried out as described.6,11
Two-month-old mice were sublethally irradiated with 750 cGy. For
i.r. injection, an abdominal incision was made to expose the left
kidney. Using a 1 ml syringe and 30 G needle, 50 ml (2 107 cells/ml)
BM cells was injected into the renal parenchyma about 2–3 mm
beneath the renal capsule. The needle was kept in position for 15 s
before withdrawal to prevent leakage of injected cells and warm
1 phosphate-buffered saline-dampened non-woven cloth was
gently pressed down for 1 min to stop potential bleeding. Other
recipients received an equal number of BM cells (5 106 cells/ml,
200 ml) via tail vein injection. Engraftment was verified at the time of
being killed by fluorescence-activated cell sorter analysis of peri-
pheral blood. GFPþ donors are at times referred to as wild-type in
terms of the Wt1 locus in this study.
Urine analysis
Urine albumin and creatinine levels were quantified as described
previously.9
Histology, TEM, fluorescent immunostaining, and
Y-fluorescent in situ hybridization
After killing, kidneys were fixed in buffered formalin for 12 h,
embedded in paraffin, sectioned at 3 mm and periodic acid-Schiff
stained. To compare the degree of renal pathology, we used a
semiquantitative system on a 0–5 scale with the best (score¼ 0)
being normal histology, and the worst score of 5 being completely
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Figure 2 | BMT prevents the development of MS. (a) Comparison of
kidney histology of four different groups 6 months post-BMT. Upper
row: WT showing normal histology; K: untreated, age-matched
Wt1þ / mouse showing severe sclerosis (arrow) of glomerular tuft,
tubular dilation with protein casts, and interstitial inflammation;
middle row: a representative K-recipient of BMT via i.v. showing left
(L) and right (R) kidneys that have normal histology; bottom row: a
representative K-recipient of BMT via i.r., showing left (L) and right (R)
kidneys that are both normal, although the BM was injected into left
kidney. Paraffin sections (3 mm), original magnification  200.
(b) Podocyte number. K-mice have about half the number of
podocytes per cross-section of glomerulus compared to wild-type
controls. The BMT recipients via i.v. or i.r. all show normal podocyte
numbers 6 months after BMT. (c) TEM analysis of glomeruli. Untreated
K-mice have wide-spread focal effacement of podocyte foot
processes (arrow) and thickening of the glomerular basement
membrane. In comparison, BMT recipients (either wild-type or
K-mice) maintained (double arrow) normal podocyte foot processes,
glomerular basement membrane, and endothelial fenestration; thus,
the integrity of the ultrafiltration barrier is preserved. Bar¼ 1 mm.
i.v.
i.r.
Left Right
GFP+WT1
Figure 3 | i.r. and i.v. transplantation of BM leads to comparable
levels of renal engraftment of donor GFPþ cells. Upper row:
K-recipient of i.v. BMT; lower row: K-recipient of i.r. BMT. Green:
GFP staining and red: Wt1 staining. Left and right kidneys show
similar staining pattern in either group (i.v. or i.r.). Paraffin section
(3 mm), original magnification  200.
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sclerotic kidney as previously described.9 For TEM analysis, mice
were perfused with 2% glutaraldehyde and 2% paraformaldehyde.
Kidneys were processed for TEM according to standard protocol.
Sections were viewed on a Zeiss EM-910 (Carl Zeiss Inc.,
Oberkochen, Germany) electron microscope at 80 kV.
Although GFP was the primary tag for tracking the donor-
derived cells, fluorescent in situ hybridization for the Y chromosome
was also performed as described previously6 to verify the results
when female recipients of male BM cells were used.
Immunostaining on paraffin-embedded tissue was performed as
described,9,12 using rabbit polyclonal antibody against Wt1 (Santa
Cruz Biotechnology, CA, USA), rabbit polyclonal anti-nephrin
antibody (a kind gift from Larry Holzman, Ann Arbor, MI, USA),
goat anti-GFP (Abcam, Cambridge, MA, USA) and rat anti-mouse
CD45 (BD Biosciences, NJ, USA).
Statistical analysis
Data were analyzed using Student’s t-test with Po0.05 regarded as
statistically significant.
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